Kidney Transplant Recipients Clinical Trial
Official title:
Immune Monitoring and Calcineurin Inhibitor (CNI) Withdrawal in Low Risk Recipients of Kidney Transplantation
The study will compare how well transplanted kidneys work and the response of people's immune systems as tacrolimus, a calcineurin inhibitor (CNI), is withdrawn. In addition, this research study will evaluate whether reducing immunosuppression can decrease some of these side effects while still preventing rejection of the kidney.
Kidney transplantation is a treatment option for people with kidney disease. However, there
is still much to learn about how to best care for the transplanted kidney and keep it
functioning for a long time. Transplant recipients take immunosuppression (anti-rejection)
drugs to prevent their body from rejecting the new kidney. These drugs are used to prevent
the immune system from attacking the transplanted kidney. All anti-rejection medications
have unwanted side effects. The purpose of this study is to evaluate the safety of slowly
removing tacrolimus, a CNI.
POST STUDY TERMINATION NOTE: Although the investigators were unable to assess the primary
study end point due to early study termination,this trial supports the conclusion that risks
associated with acute rejection and donor-specific antibodies outweigh any potential
benefits of tacrolimus withdrawal, even in this highly selected, low-risk cohort of living
donor recipients treated with antithymocyte globulin induction.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01336296 -
Evaluate Effects and Safety of Pre-load Myfortic® in Transplant Patients
|
Phase 4 | |
Recruiting |
NCT01150487 -
Paired Marrow Aspirations to Assess Assays in Sensitized Renal Allograft Recipients
|
N/A | |
Recruiting |
NCT05938712 -
The Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients
|
Phase 2 | |
Completed |
NCT00217100 -
A Multivitamin Comparison Study in Kidney Transplant Recipients.
|
Phase 3 | |
Active, not recruiting |
NCT00199667 -
Concentration Controlled Versus Fixed Dose of MMF in Kidney Transplant Recipients
|
Phase 4 | |
Recruiting |
NCT04642833 -
Prostate Cancer in Renal Transplants Recipients
|
||
Not yet recruiting |
NCT05293704 -
An Open Study on the Preventive Effect of Early Mizoribine Conversion on BKV Nephropathy in Renal Transplant Recipients
|
Phase 4 | |
Completed |
NCT02555566 -
Role of Epoxyeicosatrienoic Acids in Chronic Allograft Nephropathy - The TRANSPLANT-EETs Study
|
N/A | |
Completed |
NCT01782586 -
Validation of Gene Expression Markers of Renal Allograft Functional Decline
|
||
Enrolling by invitation |
NCT02042963 -
KoreaN Cohort Study for Outcome in Patients With Kidney Transplantation (KNOW-KT)
|
N/A | |
Not yet recruiting |
NCT05702398 -
Pilot Trial of Supplemental Vitamin A and Nicotinamide
|
Early Phase 1 | |
Active, not recruiting |
NCT05425498 -
The Effects of Physical Activity Behavior Change in Kidney Transplant Recipients
|
N/A | |
Completed |
NCT01889758 -
Pharmacokinetic Studies of Tacrolimus in Transplant Patients
|
Phase 4 | |
Terminated |
NCT02268201 -
A Study to Evaluate the Efficacy and Safety in Kidney Transplant Recipients When Changed From Cyclosporine to Tacrolimus Prolonged-release Capsule or Tacrolimus Capsule
|
Phase 4 | |
Active, not recruiting |
NCT03979365 -
Envarsus XR Compared to Immediate Release Tacrolimus
|
Phase 4 | |
Recruiting |
NCT04965935 -
Efficacy, Mechanisms and Safety of SGLT2 Inhibitors in Kidney Transplant Recipients
|
Phase 3 | |
Recruiting |
NCT04444843 -
Risk Factors of Chinese Kidney Transplant Recipients DSA Based on MPA Immunosuppressive Regimen
|
Phase 4 | |
Completed |
NCT02392312 -
Observational Study to Evaluate the Safety and Efficacy of ATG-F on Kidney Transplant Recipients
|
||
Completed |
NCT02639949 -
Measuring and Improving Medication Adherence in Kidney Transplant Patients
|
N/A | |
Withdrawn |
NCT02058875 -
Cardiovascular Risk Following Conversion to Full Dose Myfortic® and Neoral® Two-hour Post Level Monitoring
|
Phase 4 |